Pediatric implications of heterozygous familial hypercholesterolemia

Wiegman, A.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Addendum

Children with familial hypercholesterolemia express inflammatory markers. Statin effect on neopterin

T Ueland¹, A Wiegman⁵, J Rodenburg⁵, B.A. Hutten⁵, L Gullestad⁴, L Ose², JJP Kastelein⁵, P Aukrust³, AG Semb²

Research Institute for Internal Medicine, Section of Lipidology and Atherosclerosis, and Section of Clinical Immunology and Infectious Diseases, Rikshospitalet, Oslo, Medical department, Bærum Hospital, Norway, Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
Background
Atherosclerotic disease involves inflammatory and immunologic mechanisms, but the sequence of immunomodulatory steps and which molecule(s) having key roles early in atherogenesis is not clear. Micro C-reactive protein (μ-CRP) is established as an inflammatory marker of atherosclerosis. Neopterin, a marker of cellular immune activation, is produced by human macrophages. HMG-Co A reductase inhibitors, statins, have been recognized as immunomodulators and reduce cardiovascular events and mortality.

Objectives
In this study we examined the levels of neopterin and μ-CRP in children with heterozygous familial hypercholesterolemia (FH) because FH has been regarded as a model of atherosclerosis. We evaluated the impact of pravastatin.

Methods
Children aged 8-18 years, with FH (n=214), were randomised in a double blind fashion and given pravastatin 20 to 40 mg bid (n=106) or placebo (n=108) and followed for 2 years. Their (n=85) unaffected siblings were followed on a yearly base as well.

Results
There were no differences between the groups concerning demographic data. The children with FH had a significant (p<0.009) elevated level of neopterin compared to normal siblings (4.89±0.21 vs 4.33±0.14 nmol/L respectively). Furthermore, 2 years of pravastatin therapy reduced the neopterin level with 15% to 4.23±0.13 nmol/L compared to placebo which had a 7% reduction (4.6±0.18 nmol/L)(p<0.001). There were no difference between the FH-children (0.11±0.02), siblings (0.10±0.03) and controls (0.07±0.03), concerning μ-CRP at baseline. Furthermore, μ-CRP increase significantly in both FH-children receiving pravastatin (0.25±0.09) and placebo (0.17±0.095)(p<0.05).

Conclusion
Our findings suggest that the cellular inflammatory marker neopterin is an early marker in the atherosclerotic process shown in this study in children with FH. This inflammatory response is modified by statins.